Crucell Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Leiden Netherlands (2000)
Status: Acquired by Johnson and Johnson (2010)

Organization Overview

First Clinical Trial
2004
NCT01405677
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Crucell B.V., Leiden, the Netherlands | Crucell Holland | Crucell Holland BV

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diphtheria (Phase 4)

Haemophilus Infections (Phase 4)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

Influenza, Human (Phase 4)

Malaria (Phase 2)

Rabies (Phase 2)

Respiratory Tract Infections (Phase 1)

Tetanus (Phase 4)

Tetany (Phase 3)

Tuberculosis (Phase 2)

Vaccinia (Phase 1)

Whooping Cough (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 43
  • # of Trial APIs: 28